-
3 weeks ago | 
evaluate.com
Harness comprehensive market analysis with Datamonitor Healthcare to identify unmet needs, anticipate future trends, and make strategic decisions that fuel sustainable growth.
-
1 month ago | 
evaluate.com | Carolyn Hall
As you probably know, Evaluate has an incredibly rich and comprehensive set of data and insight about the pharma market. This means we’re able to produce some really valuable reports, webinars and articles that provide insight around the most exciting areas of the industry. And we create rather a lot of them, which can make it hard to keep up with it all. To help, we’ve pulled together some of the key pieces of content that we’ve published so far in 2025.
-
1 month ago | 
evaluate.com | Carolyn Hall
If you follow Evaluate’s regular white papers and blogs, you may be familiar with our annual report that investigates the state of the orphan drug market. I’ve been involved in analyzing that data for the past three years, and have just finished the process for this year’s report which will be published soon. One of the key areas we always look at is the difference in the pace of growth between the orphan drug market and the wider pharma space.
-
Jan 31, 2024 | 
evaluate.com | Carolyn Hall
Our first webinar of the year is in the bag and it was a cracker! If you missed it, the on-demand version is available to watch at your convenience (I recommend a cup of tea and something sweet to go along with it, but choose whatever works for you!) Our focus was on the 2024 Preview, our annual report that looks at the top drugs, companies, potential launches and much more for the year ahead.
-
Jan 17, 2024 | 
evaluate.com | Carolyn Hall
After a year in which investor sentiment went from bad to worse, 2024 has started on a more positive note. Last week’s JP Morgan conference saw a flurry of partnership and acquisition announcements, building on the last couple of weeks of December which saw 2023’s deal making end with a bang. If the end is in sight, what can we expect from 2024?
-
Aug 2, 2023 | 
evaluate.com | Edwin Elmhirst |Elizabeth Cairns
Bristol Myers Squibb’s clotbuster Eliquis is set to be this year’s biggest selling cardiac drug, Evaluate Pharma consensus forecasts suggest – and remarkably, it is forecast to retain the crown all the way to 2028. This comes courtesy of several court rulings preventing US generic competition until that year. Indeed the remarkable aspect of the top 10 drugs lists is the longevity of these products.
-
Jul 31, 2023 | 
evaluate.com | Joanne Fagg
Eisai and Biogen’s Leqembi received full approval to treat Alzheimer’s disease last month. That was expected; what was not was that the label came with a boxed warning over Aria, a brain swelling disorder, with recommendation for ApoE4 genetic testing to assess Aria risk. Leqembi’s launch is under way with Biogen highlighting on its quarterly call that it has Medicaid coverage in 48 states so far. Elsewhere good news finally came for Verrica’s Ycanth after three previous complete response letters.
-
Jul 31, 2023 | 
evaluate.com | Lisa Urquhart
Keytruda is the gift that keeps on giving, with the PD-1 checkpoint inhibitor smashing expectations in Merck & Co’s second-quarter earnings; global sales surged 19% to $6.3bn. Merck also reported unexpectedly high sales of the HPV vaccine Gardasil, as huge demand in China pushed sales up by 47% to $2.5bn. Merck added a billion to its full-year sales guidance, taking it to $58.6-59.6bn, and shares in the group responded accordingly, rising 2% this morning before flattening.
-
Jul 27, 2023 | 
evaluate.com | Joanne Fagg
Two of this year’s biggest FDA approval decisions are due next month, that of Astellas’s Zimura and Biogen/Sage’s zuranolone. The latter is filed in major depressive disorder and postpartum depression and is expected to be approved. Zuranolone is forecast to be Biogen's biggest growth driver but questions remain on its commercial prospects given its short two-week course of therapy.
-
Jul 27, 2023 | 
evaluate.com | Edwin Elmhirst |Lisa Urquhart
While approval for Eisai-partnered Leqembi and expectations around depression treatment Zuranolone have gone someway to raise investor expectations, the group is still facing challenges to its lucrative MS franchise, including potential US biosimilar entries for Tysabri, its current top seller. As such the Reata acquisition could be seen as decisive action to shore up sales until Biogen’s bigger prospects can come online.